Heart failure among patients with multiple myeloma treated with carfilzomib-based versus non-carfilzomib-based regimens in the United States by race

Carfilzomib treatment for multiple myeloma (MM) can increase heart failure risk. This study measured related heart failure risk by race and found that although the IR of heart failure among patients with MM treated with a carfilzomib-based regimen was slightly higher, no evidence suggested the relative risk was different between White and Black patients with MM.

Read article: Science Direct